BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update

BioAge Labs, Inc. (NASDAQ:BIOA) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,085,882 shares, an increase of 82.2% from the December 31st total of 596,127 shares. Based on an average daily trading volume, of 1,128,484 shares, the days-to-cover ratio is currently 1.0 days. Currently, 3.8% of the company’s shares are short sold. Currently, 3.8% of the company’s shares are short sold. Based on an average daily trading volume, of 1,128,484 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Piper Sandler started coverage on BioAge Labs in a report on Tuesday. They issued an “overweight” rating for the company. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research report on Monday. Citigroup upped their price target on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $15.00.

Insider Buying and Selling

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares in the company, valued at $441,437.60. This represents a 54.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Paul D. Rubin sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total transaction of $216,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 347,004 shares of company stock valued at $5,673,859 over the last ninety days. Insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its holdings in shares of BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after buying an additional 270,479 shares during the period. Marshall Wace LLP lifted its position in BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after acquiring an additional 173,388 shares in the last quarter. Geode Capital Management LLC lifted its position in BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares in the last quarter. Stonepine Capital Management LLC boosted its stake in BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock worth $624,000 after purchasing an additional 101,085 shares during the period. Finally, Vanguard Group Inc. increased its holdings in BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after purchasing an additional 93,694 shares in the last quarter.

BioAge Labs Trading Down 2.1%

BIOA stock opened at $19.10 on Friday. BioAge Labs has a 1-year low of $2.88 and a 1-year high of $24.00. The firm has a market cap of $684.74 million, a PE ratio of -12.57 and a beta of 1.38. The business’s 50-day moving average price is $14.29 and its two-hundred day moving average price is $8.58.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.